Introduction
Contract development and manufacturing organizations occupy the production side of the biopharma outsourcing value chain. While CROs handle clinical trial operations, CDMOs handle the physical production of drug substances and drug products, from early process development through commercial-scale manufacturing. The global CDMO market exceeds $250 billion and is growing at 7-9% CAGR, making it one of the largest addressable markets in life sciences. For healthcare bankers, CDMOs are an increasingly active deal category, highlighted by Novo Holdings' acquisition of Catalent for $16.5 billion in 2024, one of the largest healthcare transactions of the year.
The Two Revenue Phases
Development Services
The CDMO relationship typically begins during clinical development. A biopharma company needs to manufacture drug substance for its Phase I/II clinical trials and engages a CDMO for process development, analytical method development, formulation, and clinical-scale manufacturing. These engagements are project-based, relatively small ($2-20M per program), and margin-accretive because the CDMO is providing specialized scientific expertise alongside manufacturing capability.
Development services function as a lead generation engine for commercial manufacturing. If the drug succeeds in clinical trials and receives FDA approval, the biopharma sponsor almost always continues manufacturing with the same CDMO because switching manufacturers requires a new FDA filing (a Chemistry, Manufacturing, and Controls supplement) that can take 12-18 months and cost $5-15M. This regulatory switching cost creates powerful lock-in.
- Chemistry, Manufacturing, and Controls (CMC) Filing
The section of a drug application submitted to the FDA that describes the drug's manufacturing process, quality controls, stability data, and specifications. Any change in manufacturing site, process, or formulation requires a supplemental CMC filing, which must be reviewed and approved before the sponsor can begin commercial production at the new site. This regulatory requirement creates the primary switching cost in CDMO relationships: once a drug is approved with a specific CDMO's manufacturing process, moving to a different CDMO is expensive, time-consuming, and risky.
Commercial Manufacturing
Commercial supply is where the volume and recurring revenue materialize. Once a drug is approved, the CDMO manufactures it at commercial scale under long-term supply agreements, typically 3-7 years with renewal options. Revenue is driven by volume (units produced), pricing (cost-per-unit or cost-plus), and capacity utilization (how fully the CDMO's manufacturing assets are deployed).
Small Molecule vs. Biologics vs. Specialty Modalities
The CDMO industry segments by manufacturing modality, and each segment has a fundamentally different competitive landscape, margin profile, and growth trajectory.
| Segment | Market Size | Growth Rate | Margin Profile | Key Players |
|---|---|---|---|---|
| Small molecule | ~$120B | 4-6% | Lower (commoditized) | Lonza, Catalent, Recipharm |
| Biologics | ~$80-90B | 8-12% | Higher (complex) | Samsung Biologics, Lonza, WuXi Biologics |
| Specialty (ADC, CGT, peptide) | ~$20-30B | 15-25% | Highest (scarce capacity) | Lonza, Wuxi, specialty players |
Small molecule manufacturing is the most mature and commoditized segment. The chemistry is well-understood, equipment is relatively standardized, and global capacity is abundant. Competition from Indian and Chinese manufacturers puts pressure on Western CDMOs' pricing, though quality concerns and BIOSECURE Act dynamics are shifting some demand back to Western suppliers.
Biologics manufacturing is structurally more attractive. Producing monoclonal antibodies, recombinant proteins, and vaccines in bioreactors requires specialized facilities, highly trained staff, and rigorous quality systems that create genuine barriers to entry. A single biologics manufacturing suite can cost $200-500M to build and 3-5 years to bring online and validate.
Specialty modalities represent the highest-growth, highest-margin segment. ADC conjugation, cell and gene therapy viral vector production, and GLP-1 peptide synthesis require specialized capabilities that are in short supply globally. CDMOs with validated capacity in these areas command premium pricing and long waitlists.
Take-or-Pay Contracts and Revenue Quality
- Take-or-Pay Contract
A commercial manufacturing agreement in which the sponsor commits to purchasing a minimum volume of product (or paying for reserved capacity) regardless of actual demand. If the sponsor's drug sells less than expected, the CDMO still receives payment for the committed volume. Take-or-pay contracts are common in biologics CDMOs, where the manufacturer has dedicated specialized capacity (bioreactors, fill-finish lines) that cannot easily be repurposed. These contracts provide revenue predictability and underwrite the CDMO's capacity investment, but they also create counterparty risk if the sponsor faces financial distress.
The quality of CDMO revenue depends heavily on the contract structure. Take-or-pay agreements provide near-guaranteed revenue streams that support premium valuations. Volume-based contracts without minimums create more cyclicality and require careful analysis of the sponsor's underlying drug demand trajectory. Development-stage revenue, while higher-margin, is inherently project-based and non-recurring.
The next article covers how modality shifts in GLP-1, cell/gene therapy, and ADCs are reshaping CDMO demand and creating new investment opportunities.
Free Interview PDF Guide